Jessica Linford
Jessica Linford has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Aadel A. Chaudhuri
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
37 shared publications - Alexander D. Sherry
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
37 shared publications - Pradeep Singh Chauhan
Mayo Clinic 1 Department of Radiation Oncology Rochester, Minnesota
37 shared publications - Sean S. Park
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States
37 shared publications - Aaron Scott Mansfield
Mayo Clinic
24 shared publications - Ayesha Hashmi
Mayo Clinic 1 Department of Radiation Oncology Rochester, Minnesota
24 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Bivariate Cox regression results for ctFE with respect to survival outcomes in LA-WU, adjusted for baseline covariates.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Bivariate Cox regression results for ctFE with respect to survival outcomes in LA-WU, adjusted for baseline covariates.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in LA-RW cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in LA-RW cohort.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Circulating tumor fraction estimate (ctFE), molecular response, patterns of failure, and survival outcomes for all patients in the prospective LA-WU26 cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Circulating tumor fraction estimate (ctFE), molecular response, patterns of failure, and survival outcomes for all patients in the prospective LA-WU26 cohort.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 12: Forest plot of multivariate cox proportional hazards regression analysis comparing the prognostic value of ctFE and Max VAF using burden-based stratification in the LA-WU cohort at pre- and mid-treatment timepoints. Hazard ratios for ctFE and Max VAF are shown as squares; horizontal bars denote 95% CIs. Low ctFE: ctFE ≤0.016411, High ctFE: ctFE >0.016411; Low Max VAF: Max VAF ≤0.0138, High Max VAF: Max VAF >0.0138. CI, confidence interval; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); Max VAF, maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 12: Forest plot of multivariate cox proportional hazards regression analysis comparing the prognostic value of ctFE and Max VAF using burden-based stratification in the LA-WU cohort at pre- and mid-treatment timepoints. Hazard ratios for ctFE and Max VAF are shown as squares; horizontal bars denote 95% CIs. Low ctFE: ctFE ≤0.016411, High ctFE: ctFE >0.016411; Low Max VAF: Max VAF ≤0.0138, High Max VAF: Max VAF >0.0138. CI, confidence interval; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); Max VAF, maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Purpose:Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT).Experimental Design:In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309).Results:Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts.Conclusions:Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Purpose:Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT).Experimental Design:In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309).Results:Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts.Conclusions:Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 6: Kaplan-Meier survival analysis of OS and PFS according to baseline nonsynonymous SNV and INDEL detectability in plasma from the LA-WU and LA-RW cohorts. KM survival curves showing (A) OS and (B) PFS based on the presence of SNVs in LA-WU; (C) OS and (D) PFS based on the presence of INDELs in LA-WU; (E) OS based on SNV detectability in LA-RW; and (F) OS based on INDEL detectability in LA-RW. Mutation detectability was defined as the presence of at least one nonsynonymous variant passing assay-level filtering criteria (Methods) at baseline. Hazard ratios from univariate Cox regression analysis and log-rank p-values are shown. HR, hazard ratio; KM, Kaplan-Meier; INDELs, insertions/deletions; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); OS, overall survival; PFS, progression-free survival; SNVs, single nucleotide variants.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 6: Kaplan-Meier survival analysis of OS and PFS according to baseline nonsynonymous SNV and INDEL detectability in plasma from the LA-WU and LA-RW cohorts. KM survival curves showing (A) OS and (B) PFS based on the presence of SNVs in LA-WU; (C) OS and (D) PFS based on the presence of INDELs in LA-WU; (E) OS based on SNV detectability in LA-RW; and (F) OS based on INDEL detectability in LA-RW. Mutation detectability was defined as the presence of at least one nonsynonymous variant passing assay-level filtering criteria (Methods) at baseline. Hazard ratios from univariate Cox regression analysis and log-rank p-values are shown. HR, hazard ratio; KM, Kaplan-Meier; INDELs, insertions/deletions; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); OS, overall survival; PFS, progression-free survival; SNVs, single nucleotide variants.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 8: Comparison of survival outcomes in each cohort using different ctDNA stratification strategies—either based on ctFE detectability (undetectable: ctFE ≤0.0009, detectable: ctFE >0.0009; Methods) or high and low ctFE based on pre-treatment PFS (low: ctFE ≤0.016411, high: ctFE >0.016411; Methods). Hazard ratios from univariate Cox regression analysis for detectable vs. undetectable ctFE and for high vs. low ctFE are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); OM-RW, oligometastatic real-world NSCLC cohort (n = 309); OS, overall survival; PFS, progression-free survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 8: Comparison of survival outcomes in each cohort using different ctDNA stratification strategies—either based on ctFE detectability (undetectable: ctFE ≤0.0009, detectable: ctFE >0.0009; Methods) or high and low ctFE based on pre-treatment PFS (low: ctFE ≤0.016411, high: ctFE >0.016411; Methods). Hazard ratios from univariate Cox regression analysis for detectable vs. undetectable ctFE and for high vs. low ctFE are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); OM-RW, oligometastatic real-world NSCLC cohort (n = 309); OS, overall survival; PFS, progression-free survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in the prospective LA-WU cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in the prospective LA-WU cohort.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 13: Comparison of survival outcomes in the LA-WU cohort using different ctDNA stratification strategies. Patients were stratified by (i) Max VAF detectability (undetectable: no nonsynonymous mutations detected, detectable: at least one nonsynonymous mutation detected) or (ii) Pre-treatment PFS-derived Max VAF threshold of 0.0138 (low: ≤0.0138, high; >0.0138; Methods). Hazard ratios are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); Max VAF, Maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 13: Comparison of survival outcomes in the LA-WU cohort using different ctDNA stratification strategies. Patients were stratified by (i) Max VAF detectability (undetectable: no nonsynonymous mutations detected, detectable: at least one nonsynonymous mutation detected) or (ii) Pre-treatment PFS-derived Max VAF threshold of 0.0138 (low: ≤0.0138, high; >0.0138; Methods). Hazard ratios are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); Max VAF, Maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 14: Proposed framework for early ctFE-guided treatment adaptation during chemoRT. Pre- and mid-treatment ctFE measured with a tumor-naïve ctDNA assay (7–9- day turnaround) could enable week-3 decision support guiding systemic intensification for high ctFE or therapy de-escalation for low ctFE. ChemoRT, chemoradiotherapy; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate. Created with BioRender. Hashmi, A. (2026) https://BioRender.com/fiojbh7.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 14: Proposed framework for early ctFE-guided treatment adaptation during chemoRT. Pre- and mid-treatment ctFE measured with a tumor-naïve ctDNA assay (7–9- day turnaround) could enable week-3 decision support guiding systemic intensification for high ctFE or therapy de-escalation for low ctFE. ChemoRT, chemoradiotherapy; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate. Created with BioRender. Hashmi, A. (2026) https://BioRender.com/fiojbh7.